Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Bankruptcy or Receivership
20 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
8-K
Termination of a Material Definitive Agreement
6 Jun 23
10-Q
2023 Q2
Quarterly report
22 May 23
8-K
Departure of Directors or Certain Officers
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Departure of Directors or Certain Officers
12 May 23
8-K
Entry into a Material Definitive Agreement
4 May 23
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
5 Apr 23
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
10 Mar 23
10-Q
2023 Q1
Quarterly report
14 Feb 23
10-K
2022 FY
Annual report
13 Jan 23
NT 10-K
Notice of late annual filing
29 Dec 22
8-K
Item 9 Labs Corp. Appoints Mike Weinberger to CEO Ahead of Approaching Transformational Acquisition
30 Nov 22
8-K
Unregistered Sales of Equity Securities
11 Oct 22
8-K
Regulation FD Disclosure
16 Aug 22
10-Q
2022 Q3
Quarterly report
15 Aug 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
8-K
Item 9 Labs Corp. Signs Definitive Agreement to Acquire Sessions Cannabis, One of Canada’s Largest Cannabis Retail Franchisors
24 May 22
10-Q
2022 Q2
Quarterly report
16 May 22
8-K
Item 9 Labs Corp. Announces Second Quarter FY 2022 Financial Results with Revenue Growth of 9% to $6.6 Million
16 May 22
253G2
Offering circular supplement
4 May 22
8-K
Entry into a Material Definitive Agreement
17 Mar 22
8-K
Item 9 Labs Corp. Closes Acquisition of Adams County, Colorado Dispensary
4 Mar 22
8-K
Item 9 Labs Corp. Strengthens Board of Directors with Appointment of Massage Heights Founder
2 Mar 22
QUALIF
Notice of qualification
28 Feb 22
CORRESP
Correspondence with SEC
23 Feb 22
1-A/A
Offering $67.2M in Units, consisting of one share of Common Stock and one-half of one Warrant. Only whole warrants can be exercised to purchase one share of Common Stock from date of issuance until the second anniversary of the date of issuance.
22 Feb 22
8-K
Item 9 Labs Corp. Announces First Quarter FY 2022 Financial Results with Revenue Growth of 104% to $6.2 Million
15 Feb 22
10-Q
2022 Q1
Quarterly report
14 Feb 22
UPLOAD
Letter from SEC
8 Feb 22
1-A
Offering $42M in Units, consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock from date of issuance until the second anniversary of the date of issuance.
2 Feb 22
8-K
Departure of Directors or Certain Officers
2 Feb 22
8-K
Item 9 Labs Corp. Reports Record FY 2021 Annual Financial Results with Revenue Growth of 170% to $21.9 Million Revenue
18 Jan 22
10-K
2021 FY
Annual report
13 Jan 22
8-K
Regulation FD Disclosure
11 Jan 22
8-K
Item 9 Labs Corp. Enhances Board of Directors with Two Independent Appointments
4 Jan 22
Latest ownership filings
SC 13G
Clearthink Capital Partners, LLC
21 Feb 24
3
Eric Kutscher
10 Jan 22
3
Lawrence X. Taylor III
10 Jan 22
3
Douglas P Bowden
5 Apr 21
3
MICHAEL P KESKEY
13 Aug 20
4
Bryce Skalla
11 Sep 19
4
Andrew Poirier
10 Sep 19
4
Patrick Sean Dugan
10 Sep 19
3
Ronald L. Jr. Miller
29 Aug 19
3
Bryce Skalla
29 Aug 19
3
Andrew Douglas Bowden
28 Aug 19
3
Andrew Poirier
28 Aug 19
3
Christopher Leland Wolven
28 Aug 19
3
Robert E Mikkelsen
28 Aug 19
3
Initial statement of insider ownership
28 Aug 19
3
Sara Gullickson
28 Aug 19
3
Patrick Sean Dugan
28 Aug 19
5
Annual statement of changes in insider ownership
16 Nov 16
5
Ronald L. Jr. Miller
15 Nov 16
5
DANIEL E MD COHEN
15 Nov 16
5
Jessica L Smith
15 Nov 16
3
Christopher Larson
19 Feb 16
5
Ronald L. Jr. Miller
14 Jan 16
5
Jessica L Smith
14 Jan 16